Your Account
Biologics for the Treatment of Rheumatoid Arthritis
(To see other currencies, click on price)
Add to basket  


Main description:

This book provides a comprehensive overview of the available biologic
therapies whilst comparing them to standard disease modifying
anti-rheumatic drugs, and discusses how best to determine which therapy
is most appropriate for an individual patient in the framework of
current guidelines. Biologics for the Treatment of Rheumatoid Arthritis is an up-to-date and concise practical guide to the latest therapeutic developments in this field. This book is an invaluable source of topical information for all rheumatologists and health care professionals treating patients with rheumatoid arthritis.


A practical evidence-based overview of the available and emerging biologic treatments for rheumatoid arthritis.

This book also features a concise summary of the latest updates regarding biosimilars for this conditions.

Concise pocket-sized format makes it an ideal go-to resource for all rheumatologists treating patients with rheumatoid arthritis.

Written by an internationally renowned expert in the field.

Engaging images, illustrations, and figures highlight the up-to-date recommendations presented in the book.


Disease overview.- General treatment aspects.- Overview of biologic therapies.- Cytokine inhibitors.- B-cell directed therapy.- T-cell directed therapy.- Novel biologics and small molecules with biologic-like effects.- Strategies for the optimal use of biologic agents in rheumatoid arthritis.- Considerations for special patient populations.- Conclusions and future outlook


ISBN-13: 9783319131085
Publisher: Springer (Springer International Publishing)
Publication date: December, 2015
Pages: 100

Subcategories: Orthopaedics and Fractures, Rheumatology


Professor Ronald F van Vollenhoven is Chief of the Unit for Clinical Therapy Research,
Inflammatory Diseases (ClinTRID) at the Karolinska Institute, and of the
Clinical Trials Unit Rheumatology at the Karolinska University Hospital. He
received his MD and PhD degrees from the University of Leiden in The
Netherlands. After graduating in 1984 he pursued
immunology research at Cornell Medical College in New York, followed by a
residency (specialty training) in internal medicine at the State University of
New York at Stony Brook, and a fellowship in rheumatology at Stanford
University in Palo Alto following which he received American Board of Internal
Medicine certification in both internal medicine and rheumatology. From 1993 to
1998 Professor van Vollenhoven held a faculty appointment as Assistant
Professor of Medicine in the Division of Immunology and Rheumatology at
Stanford University, and from 1995 he was the Medical Services Chief and
Fellowship Director in that division. In 1998 Professor van Vollenhoven moved
to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the
Clinical Trials Unit in the Department of Rheumatology at the Karolinska
University Hospital and Associate Professor of Rheumatology; and in 2010, he
was appointed in his current position as Professor and Unit Chief at the
Karolinska Institute.

van Vollenhoven’s research interests focus around the development and
systematic evaluation of biologic and immunomodulatory treatments for the
rheumatic diseases. With his co-workers, he has established the Stockholm
registry for biological therapies (the STURE database) for this purpose, which
has supported research projects relating to clinical efficacy, pharmacology,
outcomes, and pharmacoeconomics. He has been principal investigator in many
clinical trials of novel therapies in rheumatic diseases and has contributed to
a number of important investigator-initiated trials including the SWEFOT trial.
He has published over 240 original papers, book chapters and reviews, and is
Editor of the textbook Targeted Treatment of the Rheumatic
and associate-editor of Dubois’ Lupus Erythematosus.
In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation
Prize for excellence in clinical research in rheumatology, and he is an
honorary member of several rheumatology societies. He is the Editor-in-Chief of
Lupus Science & Medicine, Chair of the EULAR Standing Committee on Clinical
Affairs, member of many editorial boards, past-chair of the Swedish
Rheumatology Society Professors’ Council, co-founder of the IRBIS registry for
biologics in systemic lupus erythematosus (SLE), the CERERRA registries collaboration,
and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases,
and the initiator of the Treat-to-Target-in-SLE initiative. Professor van
Vollenhoven lives just north of Stockholm with his wife and children aged 20
and 16. Outside his professional life he is an avid classical pianist.